Alzheimer’s Prevention Program & Early Intervention
An Alzheimer’s prevention program has to start decades before the first symptom, because amyloid pathology begins accumulating fifteen to twenty years before clinical onset. That window between the earliest biomarker changes and a formal diagnosis is where intervention can alter the trajectory of this disease. We are not promising reversal. We are offering interception: identifying pathology early, quantifying risk precisely, and deploying neuroprotective strategies while the biology is still modifiable.
Available at our St. Marys, Georgia clinic.
The Biology of Early Alzheimer’s
Alzheimer’s disease is not a sudden event. It is a slow cascade that unfolds over decades. The amyloid hypothesis— still the dominant framework despite legitimate debate— holds that misfolded amyloid-beta peptides begin aggregating into extracellular plaques years before any measurable cognitive symptom. These plaques trigger a downstream sequence: hyperphosphorylation of tau protein, formation of intracellular neurofibrillary tangles, chronic microglial activation, synaptic loss, and eventually neuronal death.
Jack and colleagues published a landmark biomarker model in The Lancet Neurology in 2013 that mapped this progression quantitatively. Amyloid deposition becomes detectable on PET imaging fifteen to twenty years before symptom onset. Tau pathology follows. Synaptic dysfunction and neurodegeneration accelerate as both pathologies converge. By the time a patient presents with clinical dementia, the underlying damage is advanced and largely irreversible.
Braak staging describes how tau pathology spreads through the brain in a predictable anatomical sequence—beginning in the entorhinal cortex, moving into the hippocampus and limbic structures, and eventually reaching the neocortex. Each stage corresponds to increasing clinical severity. The critical insight is that stages I and II are often clinically silent. Pathology is present, but the brain’s compensatory reserves mask it.
Neuroinflammation is not a bystander in this process. Activated microglia and elevated pro-inflammatory cytokines—IL-1 beta, TNF-alpha, IL-6—accelerate both amyloid aggregation and tau propagation. The inflammatory component represents a modifiable target. So does the metabolic environment in which these pathologies develop.
Blood Biomarkers Changing the Game
For decades, confirming Alzheimer’s pathology required either a PET scan or a lumbar puncture. Both are expensive, invasive, and inaccessible to most patients. That barrier effectively locked early detection behind a gate that only a small fraction of at-risk individuals could pass through. Blood biomarkers have changed this equation fundamentally.
Phosphorylated tau 217 has emerged as the most discriminating blood-based marker for Alzheimer’s pathology. Palmqvist and colleagues published data in JAMA in 2020 demonstrating that plasma p-Tau 217 distinguished Alzheimer’s disease from other neurodegenerative conditions with diagnostic accuracy comparable to PET imaging and cerebrospinal fluid analysis. This was a turning point. A routine blood draw can now provide information that previously required a radiolabeled tracer and a scanner.
Phosphorylated tau 181 offers a complementary signal. The amyloid beta 42/40 ratio in plasma reflects the brain’s amyloid burden—when A-beta 42 drops relative to A-beta 40 in the blood, it correlates with increased sequestration in cerebral plaques. Together, these markers can identify individuals with active Alzheimer’s pathology who are still cognitively normal or only mildly impaired.
APOE genotyping adds a layer of genetic risk stratification. The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer’s disease. One copy approximately triples the lifetime risk. Two copies increase it roughly twelvefold. APOE4 carriers clear amyloid less efficiently, which accelerates plaque accumulation. Knowing a patient’s APOE status does not diagnose disease, but it changes how aggressively we pursue neuroprotective intervention and metabolic optimization.
We use these biomarkers not as academic curiosities but as clinical decision tools. A patient with elevated p-Tau 217, a low AB42/40 ratio, and one or two copies of APOE4 has a quantifiably different risk profile than someone whose markers are clean. The treatment protocol should reflect that difference.
The Metabolic Connection
Alzheimer’s disease does not develop in a metabolic vacuum. Insulin resistance, chronic systemic inflammation, oxidative stress, and nutrient deficiencies all contribute to an environment in which amyloid and tau pathology accelerate. Addressing these contributors does not eliminate the disease, but it removes the metabolic accelerants that make it worse.
Suzanne de la Monte and colleagues at Brown University published research describing Alzheimer’s as a form of brain-specific insulin resistance—a concept they termed “type 3 diabetes.” Impaired insulin signaling in the brain reduces glucose uptake in neurons, increases oxidative damage, and promotes tau hyperphosphorylation. Patients with type 2 diabetes carry roughly double the risk of developing Alzheimer’s disease, and even prediabetic insulin resistance measurably increases vulnerability.
Dale Bredesen’s 2014 work on the reversal of cognitive decline introduced a framework for identifying the multiple metabolic and inflammatory contributors that converge in each individual patient. His protocol categorized subtypes of cognitive decline—inflammatory, atrophic, glycotoxic, toxic—and proposed that addressing the specific contributors driving each patient’s decline could produce measurable improvement. The approach has its critics, and we are careful about the word “reversal.” But the underlying logic is sound: a brain under metabolic siege degenerates faster than one that is metabolically supported.
Elevated homocysteine, low vitamin D, poor omega-3 status, disrupted sleep architecture, and chronic psychological stress each carry independent associations with accelerated cognitive decline. They are also modifiable. Our diagnostic panels measure these variables because they represent actionable targets—not because optimizing them constitutes a cure.
What This Work Can—and Cannot—Do
We want to be direct about what is realistic. Advanced neurodegeneration cannot be reversed. Neurons lost to amyloid plaques and neurofibrillary tangles do not regenerate. No therapy we offer—and no therapy that currently exists—can undo the structural damage of late-stage Alzheimer’s disease.
Our work focuses on the early and prodromal window where the biology is still modifiable. In patients with mild cognitive impairment, subjective cognitive decline, or elevated biomarkers without clinical symptoms, there is neural tissue left to protect. Reducing neuroinflammation, restoring mitochondrial function, optimizing the metabolic environment, and training compensatory cognitive networks are all achievable goals in this population.
The distinction matters. A patient with a MoCA score of 24 and elevated p-Tau 217 is in a fundamentally different biological position than a patient with advanced dementia and diffuse cortical atrophy. We are honest about where we can help and where we cannot.
Treatment Approach
Each protocol is built around the patient’s specific biomarker profile, genetic risk factors, and metabolic findings. These are the therapies we draw from.
NAD+ IV Therapy
Nicotinamide adenine dinucleotide supports mitochondrial energy production, activates sirtuins involved in DNA repair and neuroprotection, and restores the bioenergetic capacity of neurons under metabolic stress. NAD+ levels decline with age, and that decline correlates with increased vulnerability to neurodegeneration.
Exosome Therapy
Extracellular vesicles that cross the blood-brain barrier and deliver anti-inflammatory signaling molecules, growth factors, and regulatory microRNAs. Preclinical data suggests exosomes modulate microglial activation and may support amyloid clearance pathways.
NeuroCoaching
Dr. Drew Edwards works with patients on lifestyle optimization, sleep architecture, stress management, cognitive strategies, and behavioral modification. These factors are not peripheral to brain health—they are central to it. Sustained implementation is what separates a treatment plan from actual neuroprotection.
Glutathione IV Therapy
The brain’s primary endogenous antioxidant. Glutathione neutralizes reactive oxygen species generated by mitochondrial dysfunction and neuroinflammation. Oxidative stress is a documented accelerant of both amyloid and tau pathology, and glutathione depletion is consistently observed in Alzheimer’s patients.
Diagnostic Evaluation
Early intervention requires early identification. Our diagnostic workup is designed to detect pathology and quantify risk before clinical decline becomes obvious.
Blood Biomarkers
Phosphorylated tau 181 and 217, amyloid beta 42/40 ratio, and neurofilament light chain. These markers detect Alzheimer’s-related pathology from a routine blood draw with accuracy approaching that of PET imaging.
APOE Genotyping
Genetic testing for the APOE4 allele that identifies elevated risk for late-onset Alzheimer’s disease. Results guide the aggressiveness of neuroprotective strategies and metabolic optimization protocols.
Advanced Neuroimaging
PET imaging and functional MRI when clinically indicated to assess amyloid burden, regional metabolic activity, and neural network connectivity. Structural MRI for volumetric analysis of hippocampal and cortical regions.
Cognitive Testing
Beyond screening tools like the MoCA, we use detailed neuropsychological assessment measuring episodic memory, working memory, processing speed, executive function, and visuospatial performance to quantify cognitive baseline and track change over time.
Metabolic Panels
Fasting insulin and glucose, HbA1c, homocysteine, high-sensitivity CRP, IL-6, TNF-alpha, vitamin D, B12, folate, and omega-3 index. These markers identify the metabolic contributors that accelerate neurodegeneration and represent modifiable targets.
Neurogenomic Panels
Genetic variants affecting methylation, detoxification, neurotransmitter metabolism, and inflammatory response. These panels reveal why certain patients are more vulnerable to neurodegeneration and guide individualized supplementation and metabolic strategies.
Related Treatments
NAD+ IV Therapy
Restore mitochondrial bioenergetics and activate sirtuin pathways involved in DNA repair and neuroprotection. NAD+ decline is a hallmark of aging brains and a modifiable contributor to neurodegeneration.
Exosome Therapy
Extracellular vesicles that cross the blood-brain barrier and deliver anti-inflammatory signals, growth factors, and regulatory microRNAs to modulate the neuroinflammatory environment driving disease progression.
Executive Cognitive Optimization
For patients whose cognitive function is still intact but who want to build resilience, our optimization program strengthens the neural networks most vulnerable to age-related and pathological decline.
What to Expect
Risk factor assessment and family history review
Estimated time: 30 minutes
Dr. Orr conducts a detailed interview covering your family history of dementia, cardiovascular risk factors, sleep patterns, metabolic health, and any subjective cognitive concerns. This assessment identifies which risk factors are modifiable and which warrant further testing.
Cognitive testing and baseline measurement
Estimated time: 45 minutes
You complete a battery of cognitive assessments that measure memory, processing speed, executive function, and attention. These results establish a quantitative baseline that can be tracked over time to detect early changes before they become clinically apparent.
Blood biomarker testing
Estimated time: 15 minutes
Blood is drawn for biomarkers relevant to Alzheimer's risk, which may include p-tau 217, amyloid beta ratios, inflammatory markers, metabolic panels, APOE genotyping, and nutrient levels. These tests help quantify biological risk beyond what clinical assessment alone can show.
Brain imaging
Estimated time: 1 hour
Dr. Orr orders advanced brain MRI, often with volumetric analysis through NeuroQuant, to measure brain region volumes and compare them to age-matched norms. In some cases, a PET scan may be indicated to evaluate amyloid or tau deposition or regional metabolic patterns.
Personalized prevention plan
Estimated time: 30 minutes
Dr. Orr integrates all findings into a personalized prevention strategy that may include targeted supplementation, metabolic interventions, sleep optimization, exercise programming, cognitive training, and a monitoring schedule for repeat testing at defined intervals.
Frequently Asked Questions
Can you reverse Alzheimer’s disease?+
No one can reverse neurons that have already died. What we can do is intervene early, while the biology is still changeable, to slow progression, protect remaining brain tissue, and reduce the metabolic factors that accelerate decline.
Read the full answer
No one can reverse established neurodegeneration. Neurons that have died from amyloid and tau pathology do not regenerate. What we can do—and what the data supports—is intervene during the early and prodromal window when the biology is still modifiable. Slowing progression, preserving existing function, and reducing the metabolic contributors that accelerate decline are realistic and measurable goals. The earlier intervention begins, the more neural tissue there is left to protect.
How early can Alzheimer’s pathology be detected with blood tests?+
Blood tests like p-Tau 217 can now detect Alzheimer's-related changes years before memory symptoms appear. These tests do not require a spinal tap or PET scan, making early screening much more accessible than it used to be.
Read the full answer
Blood biomarkers like p-Tau 217 and the amyloid beta 42/40 ratio can now detect Alzheimer’s-related pathology years before clinical symptoms appear. Palmqvist and colleagues published data in JAMA in 2020 showing that p-Tau 217 distinguished Alzheimer’s pathology from other neurodegenerative conditions with high accuracy. These tests do not require a PET scan or lumbar puncture, which makes early screening far more accessible than it was even five years ago.
What is APOE4 and should I be tested?+
APOE4 is a gene variant that increases your risk of developing late-onset Alzheimer's. Carrying one copy roughly triples the risk. Testing tells us how aggressively to pursue prevention strategies.
Read the full answer
APOE4 is a variant of the apolipoprotein E gene that increases risk for late-onset Alzheimer’s disease. Carrying one copy roughly triples the risk compared to the general population; carrying two copies increases it further. APOE genotyping does not diagnose Alzheimer’s—it identifies genetic risk. For patients who want to understand their vulnerability and take preventive action based on that knowledge, testing provides actionable information that guides how aggressively we pursue metabolic optimization and neuroprotective strategies.
What does your diagnostic evaluation include?+
We run Alzheimer's blood biomarkers, genetic testing, metabolic panels measuring inflammation and insulin sensitivity, detailed cognitive testing, and brain imaging when indicated. The evaluation identifies both your risk level and the modifiable factors we can target.
Read the full answer
We run blood biomarkers including p-Tau 181, p-Tau 217, and the amyloid beta 42/40 ratio. APOE genotyping identifies genetic risk factors. Metabolic panels measure insulin sensitivity, HbA1c, homocysteine, and inflammatory markers that contribute to neurodegeneration. Cognitive testing goes beyond a screening MoCA to include detailed neuropsychological assessment of memory, processing speed, and executive function. Advanced neuroimaging is ordered when clinically indicated.
Who is a good candidate for your Alzheimer’s prevention program?+
People with a family history of Alzheimer's, those with mild memory complaints, anyone who carries the APOE4 gene, and people with risk factors like insulin resistance, poor sleep, or chronic inflammation. We also see patients in early symptomatic stages who want a deeper evaluation.
Read the full answer
Good candidates include individuals with a family history of Alzheimer’s who want proactive risk assessment, patients with mild cognitive impairment or subjective cognitive decline, people who have tested positive for APOE4, and anyone with metabolic risk factors—insulin resistance, chronic inflammation, sleep disruption—that are known contributors to neurodegeneration. We also see patients in the earliest symptomatic stages who want a more thorough evaluation and a treatment approach that goes beyond cholinesterase inhibitors.
Does insurance cover early Alzheimer’s intervention at your clinic?+
No. We operate outside insurance networks. We provide documentation you can submit for potential out-of-network reimbursement, and our coordinator can discuss costs and payment options before you schedule.
Read the full answer
The Neurogenesis Project operates outside of insurance networks. Our diagnostic and treatment protocols use therapies that are not typically covered by commercial insurance plans or Medicare. We provide detailed superbills and medical documentation that patients can submit to their carriers for potential out-of-network reimbursement. Our patient coordinator can discuss costs, payment plans, and documentation options before you schedule.
How accurate is the p-Tau 217 blood test for Alzheimer's detection?+
The p-Tau 217 blood test is over 90 percent accurate for detecting Alzheimer's pathology, based on validation studies involving more than 1,400 participants. It is one of the most reliable blood-based Alzheimer's biomarkers available today.
Read the full answer
The p-Tau 217 blood test has demonstrated sensitivity and specificity above 90 percent for detecting Alzheimer's pathology in multiple validation studies, including a 2024 study in JAMA Neurology involving over 1,400 participants. It measures a phosphorylated form of tau protein that correlates closely with amyloid and tau PET scan findings. This makes it one of the most accurate blood-based biomarkers currently available for Alzheimer's disease. It is not a standalone diagnostic tool, but when combined with clinical evaluation and imaging, it substantially changes how early we can identify the disease process.
At what age should I start Alzheimer's prevention screening?+
If you have a family history of Alzheimer's or carry the APOE4 gene, start at age 45. Without those risk factors, age 50 is reasonable. Alzheimer's pathology can begin 15 to 20 years before symptoms appear, so early screening creates a baseline.
Read the full answer
For patients with a first-degree family history of Alzheimer's disease or known APOE4 carrier status, I recommend baseline screening beginning at age 45. For patients without family history or known genetic risk, age 50 is a reasonable starting point. The rationale is that amyloid deposition can begin 15 to 20 years before the first clinical symptoms appear. A 2023 study in Nature Medicine confirmed that plasma p-Tau 217 elevations are detectable years before cognitive symptoms emerge. Early screening creates a baseline against which future results can be compared, and it identifies modifiable risk factors while intervention can still change the trajectory.
If I have a family history of Alzheimer's but no symptoms, when should I get tested?+
If a parent or sibling had Alzheimer's, get tested now if you are over 40. The evaluation establishes your baseline and identifies risk factors you can actually change, like insulin resistance, inflammation, sleep quality, and cardiovascular fitness.
Read the full answer
If a parent or sibling developed Alzheimer's disease, I would recommend testing now if you are over 40. The evaluation includes APOE genotyping, p-Tau 217 and other plasma biomarkers, NeuroQuant volumetric MRI to establish hippocampal and cortical baseline volumes, and a panel of metabolic and inflammatory markers that identify modifiable risk factors. Family history increases your lifetime risk, but it does not make the disease inevitable. The point of early testing is to find the variables you can actually change, which include insulin resistance, sleep quality, cardiovascular fitness, and chronic inflammation.
The Earlier You Act, the More You Can Protect
Alzheimer’s pathology does not wait for a diagnosis. If you have a family history, cognitive concerns, or simply want to know where you stand, Dr. Orr and the team at The Neurogenesis Project can quantify your risk and build a neuroprotective strategy around what the data shows. We are accepting new patients in St. Marys, Georgia.